TCGA-C8-A12Y-01A-11R-A12D-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 49
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.620
- ESTROGEN_RESPONSE_LATE+0.420
- INTERFERON_GAMMA_RESPONSE+0.410
- ESTROGEN_RESPONSE_EARLY+0.400
- COAGULATION+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- OXIDATIVE_PHOSPHORYLATION+0.250
- APOPTOSIS+0.240
- PANCREAS_BETA_CELLS+0.200
Top 10 suppressed
- MITOTIC_SPINDLE-0.420
- PROTEIN_SECRETION-0.320
- HEDGEHOG_SIGNALING-0.300
- ANDROGEN_RESPONSE-0.250
- UV_RESPONSE_DN-0.240
- G2M_CHECKPOINT-0.230
- KRAS_SIGNALING_UP-0.230
- WNT_BETA_CATENIN_SIGNALING-0.180
- INFLAMMATORY_RESPONSE-0.170
- ALLOGRAFT_REJECTION-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0RH-01A-21R-A115-07 | — | B | 0.832 |
| 2 | TCGA-E9-A6HE-01A-11R-A31O-07 | — | B | 0.749 |
| 3 | TCGA-LL-A6FQ-01A-11R-A31O-07 | — | B | 0.732 |
| 4 | 9c8140ab-454c-4f62-aa6e-d1cfe4e498e0 | — | — | 0.725 |
| 5 | TCGA-E9-A1NI-01A-11R-A14D-07 | — | C | 0.722 |
| 6 | MDT-AP-2585 | Med | Medulloblastoma | 0.702 |
| 7 | MBCProject_2517_T1_RNA | — | B | 0.693 |
| 8 | SJEPD001516_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.689 |
| 9 | MNG956 | — | — | 0.684 |
| 10 | 47661ed9-5c0e-442d-b072-3da8b14fab02 | — | — | 0.683 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.620 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.420 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |